Clinical Trials & Research Operations · Healthcare & Life Sciences
Should you build or buy Randomization & Trial Supply Management (RTSM/IRT)?
Randomization and Trial Supply Management (RTSM), also called Interactive Response Technology (IRT), is the software that controls patient treatment assignment and drug supply logistics throughout a clinical trial. It executes the randomization schema at enrollment, manages stratification factors, coordinates kit dispensing at sites, runs supply forecasting models against active enrollment data, and maintains the blinded audit trail that regulators require to verify trial integrity.
The build-vs-buy decision for RTSM/IRT turns on how deeply study-specific the randomization and supply logic is and how far the per-study regulatory validation requirement creates an economic reset that changes the build calculus on every trial; the complexity of your adaptive design and global supply chain footprint decide it.
Build it, buy it, or bridge?
When building makes sense
RTSM presents one of the more demanding cases in clinical software, and honest analysis starts there. The per-study validation requirement means that building a production-grade validated IRT system isn't a one-time cost — it resets economically on every trial, because FDA and EMA expect study-specific validation documentation regardless of whether the platform is in-house or vendor-supplied. That said, the configuration layer carries real sponsor-specific logic. Randomization schemas, stratification factors, and supply buffer calculations encode the statistical strategy of the trial itself, and two sponsors running the same molecule will have materially different RTSM configurations. For a large sponsor running a high-volume adaptive design portfolio where supply forecasting algorithms represent genuine competitive IP — faster drug waste reduction, tighter emergency resupply windows — there is an argument for owning the algorithmic layer above the validated platform core. The practical path is less a full build and more extending a vendor platform's open APIs with proprietary supply intelligence, rather than replacing the validated randomization engine underneath.
When buying makes sense
Buying earns its keep for nearly every realistic sponsor profile. The regulatory validation burden is the structural argument: per-study validation packages are required by FDA and EMA, and purpose-built vendors like Endpoint Clinical PULSE, Suvoda, and Veeva Vault RTSM have refined that process over hundreds of studies. The per-study certification requirement effectively resets the economics on every trial, which means a self-built platform never achieves the amortization that would make it cost-competitive. Beyond compliance, vendors bring established integrations with global depot networks, site IVR/IWR interfaces, and CTMS and EDC systems — infrastructure that a first-build team would need years to replicate. Randomization integrity is foundational to trial validity: protocol deviations in treatment assignment or supply can compromise the study and delay or prevent approval. That risk profile, combined with the compliance overhead, makes buying the sensible default for sponsors managing an active Phase 2 and 3 pipeline.
The desk read
Randomization schemas, stratification factors, and supply buffer calculations are study-specific. Two sponsors running the same molecule will have materially different RTSM configurations because the platform encodes the statistical strategy itself, beyond the software. Vendors like Endpoint Clinical PULSE, Suvoda, and Veeva Vault RTSM have built their businesses around per-study implementations, and the study-level validation packages required by FDA and EMA are part of what you're buying.
Self-building a production-grade validated IRT system isn't realistic for most sponsors. The regulatory validation burden alone, separate from the CTMS and EDC integrations, is substantial. Buying earns its keep whenever the compliance overhead of a self-built system would require a dedicated internal team to maintain study-level validation documentation across an active pipeline. The per-study certification requirement effectively resets the economics on every trial, which keeps this category firmly in the buy column even for large sponsors.
Frequently asked
What is Randomization and Trial Supply Management (RTSM/IRT) software?
RTSM/IRT software controls patient treatment assignment and drug supply logistics throughout a clinical trial. It executes the randomization schema at enrollment, manages stratification factors, coordinates kit dispensing at sites, runs supply forecasting models, and maintains the blinded audit trail that regulators require to verify trial integrity.
When does building RTSM/IRT make sense?
A full self-build is not realistic for most sponsors given the per-study regulatory validation requirement — the economics reset on every trial. The credible case is extending a vendor platform's open APIs with proprietary supply forecasting or adaptive randomization algorithms, rather than building the validated randomization engine from scratch.
When does buying RTSM/IRT make sense?
Buying is the default for any sponsor running a randomized Phase 2 or Phase 3 trial — vendors like Endpoint Clinical PULSE and Suvoda deliver per-study validation packages, established depot and site integrations, and supply forecasting infrastructure that a self-built system would take years to replicate while resetting its cost basis on every new protocol.
What are the main RTSM/IRT vendors?
Representative vendors include Endpoint Clinical (PULSE), Suvoda, Calyx (IRT), Veeva Vault RTSM. B4 Pro scores the full set.
What is the difference between RTSM and IRT in clinical trials?
IRT (Interactive Response Technology) is the older term for the telephone and web-based systems used to manage randomization and supply. RTSM (Randomization and Trial Supply Management) is the modern name reflecting that the system now handles the full supply chain — forecasting, depot coordination, kit dispensing, and resupply — beyond just the randomization call. The terms are used interchangeably in vendor marketing and regulatory submissions.